Dupixent® (dupilumab)approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Approximately seven […]
Dupixent®(dupilumab) late-breaking dataat AAD show significant improvements in signs and symptomsofmoderate-to-severe atopic hand and foot dermatitis More than twice as many patients on Dupixent achieved […]
Dupixent® (dupilumab)applicationfor treatment ofchronic spontaneous urticaria (CSU) inadults and adolescents accepted for FDA review More than 300,000 people in the U.S. suffer from CSU that […]
[27.02.23] PRESS RELEASE FEBRUARY 2023 AUDIENCES TF1 group no.1 on targets: Clear market leader status on target audiences confirmed: 32.7% share of W<50PDM1 and of […]
Press Release Nokia bolsters MX Industrial Edge capabilities to meet ever-growing industry digitalization demands #MWC23 Nokia MXIE to leverage high-performance Dell PowerEdge server family to […]
Reuters Jakarta ● Thu, February 9, 2023 2023-02-09 15:04 0 … Source link
■ New FC-BGA Substrate unveiled in the CES 2023 <_o3a_p> ■ 1st Significant production achievedin last year, Full-Scale Production will be possible in the 2nd […]
Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP totreat children as young as six months old with severe atopic dermatitis If approved, Dupixent […]
NEW DELHI: The Indian Newspaper Society (INS) on Tuesday urged the government to drop the draft amendment to the IT Rules that requires social media […]
With regards to public service broadcasting, the press information bureau from the Government of India announced that the Cabinet Committee on Economic Affairs (CCEA) has […]